Noven Receives Warning Letter

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Noven Pharmaceuticals received a warning letter from the US Food and Drug Administration stemming from an on-site inspection of the company?s manufacturing facility in Miami, Florida, concluded July 2007.

Miami, FL (Jan. 10)-Noven Pharmaceuticals received a warning letter from the US Food and Drug Administration stemming from an on-site inspection of the company’s manufacturing facility in Miami, Florida, concluded July 2007. At that time, the company’s Form 483 observations related to “difficulties experienced by some patients in removing the release liner of the Daytrana transdermal system.”

Although the warning letter does not restrict production or shipment of the company’s Daytrana product, it does request additional information and analysis related to the cited deficiencies. In particular, the warning letter points to deficiencies related to peel-force specifications for release-liner removal and data supporting the peel-force characteristics of the products “enhanced” release liner through its shelf life.

According to a company announcement, Jeffrey F. Eisenberg, Noven’s interim CEO, said, “We are working very closely with Shire, the global licensee of Daytrana, to promptly respond to the FDA’s letter, and we are committed to working collaboratively with the FDA to fully resolve the issues.”

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes